Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers.

Cervical Cancer Ovarian Cancer Palliative Care Quality of Life Uterine Cancer

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
31 May 2024
Historique:
medline: 1 6 2024
pubmed: 1 6 2024
entrez: 31 5 2024
Statut: aheadofprint

Résumé

Implementation of an interprofessional program at Princess Margaret Cancer Centre, including nurse-led proactive calls to support patients with gynecologic cancers with malignant bowel obstruction, demonstrated improved outcomes compared with historical controls. The aim of the study was to convert the proactive calls into an electronic monitoring program to assess it's feasibility and scalability in patients with gynecologic cancers with or at risk of malignant bowel obstruction. 'My Bowels on Track' smartphone application included weekly/biweekly electronic patient-reported outcomes (PROs), educational materials, and a secure messaging system. Based on PRO answers, an alerting system flagged patients with symptoms or uncompleted PROs. Nurses tracked and called patients on receiving clinical or compliance alerts. The primary objective was to assess adherence (≥70% PRO completion per patient considered an adherent patient) in the first 2 months on the program. A secondary objective was to assess the positive predictive value (PPV) of the alerts to trigger recommendations. Forty patients were enrolled between August 2021 and September 2022. Median age was 64.5 years (range 29-79 years). Primary diagnosis was ovarian (75%), endometrial (17.5%), or cervical (7.5%) cancer, and 92.5% of patients were receiving systemic therapy. Median duration on the program was 55 days (range 8-121 days). The 2-month adherence was 65% (95% CI 50% to 80%) and the overall adherence was 60% (95% CI 43% to 75%). Sixty-five symptom-related alerts (75% severe, 25% moderate) were reported in 60% (24/40) of patients. There were 59 recommendations triggered by the alerts. The PPV of the alerts to trigger actions was 72% (95% CI 58% to 82%). This pilot electronic malignant bowel obstruction monitoring program with real-time PRO assessment was feasible, and 65% of participants were adherent during the first 2 months on the program. The PRO response-based alerting system flagged concerning symptoms in 60% of participants, with a PPV of 72% to trigger nurse-led actions and/or management recommendations. NCT03260647.

Identifiants

pubmed: 38821545
pii: ijgc-2024-005490
doi: 10.1136/ijgc-2024-005490
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03260647']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Ainhoa Madariaga (A)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.

Nazlin Jivraj (N)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Pamela Soberanis Pina (P)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Faiza Somji (F)

Cancer Digital Intelligence, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Tran Truong (T)

Cancer Digital Intelligence, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Sheena Melwani (S)

Cancer Digital Intelligence, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Mike Lovas (M)

Cancer Digital Intelligence, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Terri-Ann Gogos (TA)

Patient Advocate, Toronto, Ontario, Canada.

Katrina Sajewycz (K)

Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Gita Bhat (G)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Husam Alqaisi (H)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Eduardo Gonzalez-Ochoa (E)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Ana Veneziani (A)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Vikas Garg (V)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Neesha C Dhani (NC)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Robert Grant (R)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Valerie Bowering (V)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Amit M Oza (AM)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Lisa Wang (L)

Department of Biostatistics, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Alejandro Berlin (A)

Cancer Digital Intelligence, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Radiation Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Stephanie Lheureux (S)

Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada Stephanie.Lheureux@uhn.ca.

Classifications MeSH